Alpha Teknova, Inc. (“Teknova” or the “Company”) (Nasdaq: TKNO), a
leading provider of critical reagents for the discovery, research,
development, and commercialization of drug therapies, novel
vaccines, and molecular diagnostics, today announced financial
results for the third quarter ended September 30, 2022.
“Teknova delivered a solid third quarter revenue
performance, driven by robust Lab Essentials growth and healthy
demand across our broad customer base,” said Stephen Gunstream,
President and CEO of Teknova. “Most recently, we entered the
qualification phase of our new state-of-the-art production facility
and announced an Early Access Program for the first novel products
to emerge from our R&D pipeline. We are balancing selective
strategic investments with prudent management of our capital to
position Teknova for accelerated growth and remain on our path to
profitability.”
Corporate and Financial
Updates
- Achieved quarterly total revenue of $10.7 million, up 14%
compared to $9.4 million in the third quarter 2021
- Remained on track with capacity expansion of existing
facilities and are nearing completion of the Company’s new,
state-of-the-art manufacturing facility. Qualification activities
are underway, and facility expected to be operational for
production of research grade products by the end of 2022
- Reported cash position of $49.9 million, supporting ongoing
investment in future growth
- Introduced an Early Access Program for two novel products in
development and added WFI Quality Water to the Company’s product
portfolio
- Goodwill was fully impaired, resulting in a one-time, non-cash
impairment charge of $16.6 million in the third quarter 2022
Revenue for the Third Quarter and
Year-to-Date 2022
|
|
For the Three Months EndedSeptember 30, |
|
|
For the Nine Months EndedSeptember 30, |
|
|
|
2022 |
|
|
2021 |
|
|
2022 |
|
|
2021 |
|
Lab Essentials |
|
$ |
9,470 |
|
|
$ |
7,195 |
|
|
$ |
24,838 |
|
|
$ |
20,440 |
|
Clinical Solutions |
|
|
919 |
|
|
|
1,690 |
|
|
|
7,673 |
|
|
|
4,354 |
|
Sample Transport |
|
|
— |
|
|
|
73 |
|
|
|
6 |
|
|
|
1,035 |
|
Other |
|
|
303 |
|
|
|
434 |
|
|
|
1,012 |
|
|
|
954 |
|
Total revenue |
|
$ |
10,692 |
|
|
$ |
9,392 |
|
|
$ |
33,529 |
|
|
$ |
26,783 |
|
Third Quarter 2022 Financial
Results
Total revenue for the third quarter 2022 was $10.7
million, up 14% compared to $9.4 million in the third quarter
2021.
Gross profit for the third quarter 2022 was $4.8
million, compared to $4.3 million in the third quarter 2021. Gross
margin for the third quarter 2022 was 44.6% of revenue. This
compares to gross margin of 45.4% in the third quarter 2021. The
lower gross margin for the third quarter 2022 compared to the gross
margin in the prior year primarily reflects additional headcount
resulting in higher labor costs.
Operating expenses for the third quarter 2022 were
$27.7 million compared to $8.2 million in the third quarter 2021.
The increase was primarily related to a one-time, $16.6 million
non-cash goodwill impairment charge in the quarter, coupled with
additional headcount, stock-based compensation expense, and
marketing costs.
Net loss for the third quarter 2022 was $22.5
million, or negative $0.80 per diluted share, compared to net loss
of $3.3 million, or negative $0.12 per diluted share, for the third
quarter 2021.
Cash used in operating activities for the third
quarter 2022 was $8.3 million, compared to cash used in operating
activities of $4.8 million for the third quarter 2021.
Adjusted EBITDA for the third quarter 2022 was
negative $4.6 million, compared to negative $2.7 million for the
third quarter 2021. Free Cash Flow was negative $14.9 million for
the third quarter 2022, compared to negative $8.7 million for the
third quarter 2021.
2022 Revenue Outlook
Teknova is updating its outlook for the fiscal
year ending December 31, 2022, to total revenue of $40 million to
$42 million, which assumes approximately 16% growth at the
mid-point of guidance, excluding Sample Transport revenue earned in
2021. The Company expects an approximately 15% increase in Lab
Essentials and at least a 25% increase in Clinical Solutions
revenue to drive total revenue growth for the year. The Company
does not anticipate any material revenue from Sample Transport in
2022.
Conference Call and Webcast
Teknova will host a webcast and conference call on
Wednesday, November 9, 2022, beginning at 4:30 p.m. ET.
Participants can access the live webcast on the Investor Relations
section of the Teknova website and at this link:
https://edge.media-server.com/mmc/p/rjjxxr67. To receive a PIN
number for dial in, participants can register for the webcast via
this link:
https://register.vevent.com/register/BIc8c72fb8e9214c49b689933915e724ad.
The webcast will be available for replay on the Company’s website
approximately two hours after the event.
About Teknova
Teknova is expediting clinical breakthroughs in
life sciences by providing custom products and reagents for drug
therapies, novel vaccines, and molecular diagnostics. With a focus
on agility and customization, Teknova delivers research-grade and
GMP products, including cell culture media and supplements, protein
and nucleic acid purification buffers, and molecular biology
reagents for a multitude of established and emerging applications,
including cell and gene therapy, mRNA therapeutics, genomics, and
synthetic biology. Teknova's proprietary processes enable the
manufacture and delivery of high-quality, custom, made-to-order
products with short turnaround times and at scale across all stages
of development, including commercialization.
Non-GAAP Financial Measures
This press release contains financial measures
that have not been calculated in accordance with U.S. generally
accepted accounting principles (GAAP). Teknova uses the following
non-GAAP financial measures in assessing the performance of its
business and the effectiveness of its business strategies: (a)
Adjusted EBITDA and (b) Free Cash Flow.
Teknova defines Adjusted EBITDA as net loss
adjusted for interest income (expense), net, benefit from income
taxes, depreciation expense, amortization of intangible assets, and
stock-based compensation expense. Adjusted EBITDA reflects further
adjustments to eliminate the impact of certain items, including
certain non-cash and other items that Teknova does not consider
representative of its ongoing operating performance.
Teknova defines Free Cash Flow as cash used in
operating activities less purchases of property, plant, and
equipment.
Teknova presents Adjusted EBITDA and Free Cash
Flow in this press release because Teknova believes that analysts,
investors, and other interested parties frequently use these
measures to evaluate companies in Teknova's industry and that such
measures facilitate comparisons on a consistent basis across
reporting periods. Teknova also believes such measures are helpful
in highlighting trends in Teknova's operating results because they
exclude items that are not indicative of Teknova's core operating
performance. Investors should consider non-GAAP financial measures
in addition to, and not as a substitute for, or as superior to,
measures of financial performance prepared in accordance with GAAP.
The non-GAAP financial measures presented by Teknova may be
different from the non-GAAP financial measures used by other
companies.
A full reconciliation of these non-GAAP measures
to the most comparable GAAP measures is included at the end of this
release.
Forward-Looking Statements
Statements in this press release about future
expectations, plans and prospects, as well as any other statements
regarding matters that are not historical facts, may constitute
“forward-looking statements.” These statements include, but are not
limited to, statements relating to Teknova’s anticipated total
revenue, expected growth in Lab Essentials and Clinical Solutions,
ongoing capacity expansion, new research and development products,
prospects, including to achieve profitability, and long-term growth
strategy. The words, without limitation, “anticipate,” “believe,”
“continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,”
“potential,” “predict,” “project,” “should,” “target,” “will,”
“would” and similar expressions are intended to identify
forward-looking statements, although not all forward-looking
statements contain these or similar identifying words. These
forward-looking statements are based on management’s current
expectations and beliefs and are subject to uncertainties and
factors, all of which are difficult to predict and many of which
are beyond Teknova’s control and could cause actual results to
differ materially and adversely from those described in the
forward-looking statements. These risks include, but are not
limited to, demand for Teknova’s products (including the delay or
pausing of customer orders); Teknova’s assessment of fundamental
indicators of future demand across its target customer base;
Teknova’s ability to expand its production capacity and commercial
and R&D capabilities; Teknova’s cash flows and revenue growth
rate; Teknova’s supply chain, sourcing, manufacturing and
warehousing; inventory management; risks related to global economic
and marketplace uncertainties related to the impact of the COVID-19
pandemic, including the impact of the pandemic on Teknova’s supply
chain; reliance on a limited number of customers for a high
percentage of Teknova’s revenue; potential acquisitions and
integration of other companies and other factors discussed in the
“Risk Factors” section of Teknova’s most recent periodic reports
filed with the Securities and Exchange Commission (“SEC”),
including in Teknova’s Annual Report on Form 10-K for the year
ended December 31, 2021 and subsequent Quarterly Reports on Form
10-Q filed with the SEC, all of which you may obtain for free on
the SEC’s website at www.sec.gov. Although Teknova believes that
the expectations reflected in its forward-looking statements are
reasonable, Teknova does not know whether its expectations will
prove correct. You are cautioned not to place undue reliance on
these forward-looking statements, which speak only as of the date
hereof, even if subsequently made available by Teknova on its
website or otherwise. Teknova does not undertake any obligation to
update, amend or clarify these forward-looking statements, whether
as a result of new information, future events or otherwise, except
as may be required under applicable securities laws.
ALPHA TEKNOVA, INC.
Condensed Statements of Operations
(Unaudited) (In thousands, except share
and per share data)
|
|
For the Three Months EndedSeptember 30, |
|
|
For the Nine Months EndedSeptember 30, |
|
|
|
2022 |
|
|
2021 |
|
|
2022 |
|
|
2021 |
|
Revenue |
|
$ |
10,692 |
|
|
$ |
9,392 |
|
|
$ |
33,529 |
|
|
$ |
26,783 |
|
Cost of sales |
|
|
5,922 |
|
|
|
5,129 |
|
|
|
18,163 |
|
|
|
14,141 |
|
Gross profit |
|
|
4,770 |
|
|
|
4,263 |
|
|
|
15,366 |
|
|
|
12,642 |
|
Operating expenses: |
|
|
|
|
|
|
|
|
|
|
|
|
Research and development |
|
|
1,925 |
|
|
|
1,372 |
|
|
|
5,867 |
|
|
|
2,922 |
|
Sales and marketing |
|
|
2,397 |
|
|
|
885 |
|
|
|
6,592 |
|
|
|
2,494 |
|
General and administrative |
|
|
6,502 |
|
|
|
5,607 |
|
|
|
20,856 |
|
|
|
13,606 |
|
Amortization of intangible assets |
|
|
287 |
|
|
|
287 |
|
|
|
861 |
|
|
|
861 |
|
Goodwill impairment |
|
|
16,613 |
|
|
|
— |
|
|
|
16,613 |
|
|
|
— |
|
Total operating expenses |
|
|
27,724 |
|
|
|
8,151 |
|
|
|
50,789 |
|
|
|
19,883 |
|
Loss from operations |
|
|
(22,954 |
) |
|
|
(3,888 |
) |
|
|
(35,423 |
) |
|
|
(7,241 |
) |
Other income (expenses), net |
|
|
|
|
|
|
|
|
|
|
|
|
Interest income (expense), net |
|
|
70 |
|
|
|
(255 |
) |
|
|
85 |
|
|
|
(553 |
) |
Other income (expense), net |
|
|
36 |
|
|
|
— |
|
|
|
36 |
|
|
|
(2 |
) |
Total other income (expenses), net |
|
|
106 |
|
|
|
(255 |
) |
|
|
121 |
|
|
|
(555 |
) |
Loss before income taxes |
|
|
(22,848 |
) |
|
|
(4,143 |
) |
|
|
(35,302 |
) |
|
|
(7,796 |
) |
Benefit from income taxes |
|
|
(374 |
) |
|
|
(892 |
) |
|
|
(1,128 |
) |
|
|
(1,640 |
) |
Net loss |
|
$ |
(22,474 |
) |
|
$ |
(3,251 |
) |
|
$ |
(34,174 |
) |
|
$ |
(6,156 |
) |
Net loss per share—basic and diluted |
|
$ |
(0.80 |
) |
|
$ |
(0.12 |
) |
|
$ |
(1.22 |
) |
|
$ |
(0.51 |
) |
Weighted average shares used in computing net loss per share—basic
and diluted |
|
|
28,090,267 |
|
|
|
28,011,917 |
|
|
|
28,059,897 |
|
|
|
12,069,214 |
|
ALPHA TEKNOVA, INC.
Condensed Balance Sheets
(Unaudited) (In thousands)
|
|
As of September 30, |
|
|
As of December 31, |
|
|
|
2022 |
|
|
2021 |
|
ASSETS |
|
|
|
|
|
|
Current assets: |
|
|
|
|
|
|
Cash and cash equivalents |
|
$ |
49,855 |
|
|
$ |
87,518 |
|
Accounts receivable, net |
|
|
5,581 |
|
|
|
4,666 |
|
Contract assets |
|
|
667 |
|
|
|
— |
|
Inventories, net |
|
|
10,323 |
|
|
|
5,394 |
|
Income taxes receivable |
|
|
120 |
|
|
|
1,188 |
|
Prepaid expenses and other current assets |
|
|
3,521 |
|
|
|
2,438 |
|
Total current assets |
|
|
70,067 |
|
|
|
101,204 |
|
Property, plant and equipment, net |
|
|
52,628 |
|
|
|
29,810 |
|
Operating right-of-use lease assets |
|
|
18,558 |
|
|
|
— |
|
Goodwill |
|
|
— |
|
|
|
16,613 |
|
Intangible assets, net |
|
|
17,843 |
|
|
|
18,704 |
|
Other non-current assets |
|
|
1,176 |
|
|
|
180 |
|
Total assets |
|
$ |
160,272 |
|
|
$ |
166,511 |
|
LIABILITIES AND STOCKHOLDERS’ EQUITY |
|
|
|
|
|
|
Current liabilities: |
|
|
|
|
|
|
Accounts payable |
|
$ |
3,485 |
|
|
$ |
2,248 |
|
Accrued liabilities |
|
|
6,590 |
|
|
|
5,495 |
|
Current portion of operating lease liabilities |
|
|
2,253 |
|
|
|
— |
|
Total current liabilities |
|
|
12,328 |
|
|
|
7,743 |
|
Deferred tax liabilities |
|
|
2,028 |
|
|
|
3,153 |
|
Other accrued liabilities |
|
|
212 |
|
|
|
273 |
|
Long-term debt, net |
|
|
16,878 |
|
|
|
11,870 |
|
Deferred rent |
|
|
— |
|
|
|
269 |
|
Long-term operating lease liabilities |
|
|
16,830 |
|
|
|
— |
|
Total liabilities |
|
|
48,276 |
|
|
|
23,308 |
|
Stockholders’ equity: |
|
|
|
|
|
|
Preferred stock |
|
|
— |
|
|
|
— |
|
Common stock |
|
|
— |
|
|
|
— |
|
Additional paid-in capital |
|
|
153,708 |
|
|
|
150,741 |
|
Accumulated deficit |
|
|
(41,712 |
) |
|
|
(7,538 |
) |
Total stockholders’ equity |
|
|
111,996 |
|
|
|
143,203 |
|
Total liabilities and stockholders’ equity |
|
$ |
160,272 |
|
|
$ |
166,511 |
|
ALPHA TEKNOVA, INC.
Condensed Statements of Cash Flows
(Unaudited) (In thousands)
|
|
For the Three Months EndedSeptember 30, |
|
|
For the Nine Months EndedSeptember 30, |
|
|
|
2022 |
|
|
2021 |
|
|
2022 |
|
|
2021 |
|
Operating activities: |
|
|
|
|
|
|
|
|
|
|
|
|
Net loss |
|
$ |
(22,474 |
) |
|
$ |
(3,251 |
) |
|
$ |
(34,174 |
) |
|
$ |
(6,156 |
) |
Adjustments to reconcile net loss to net cash used in operating
activities: |
|
|
|
|
|
|
|
|
|
|
|
|
Bad debt expense |
|
|
2 |
|
|
|
4 |
|
|
|
34 |
|
|
|
235 |
|
Inventory reserve |
|
|
186 |
|
|
|
(23 |
) |
|
|
178 |
|
|
|
676 |
|
Depreciation and amortization |
|
|
729 |
|
|
|
748 |
|
|
|
2,272 |
|
|
|
2,100 |
|
Stock-based compensation |
|
|
968 |
|
|
|
442 |
|
|
|
2,689 |
|
|
|
927 |
|
Deferred taxes |
|
|
(374 |
) |
|
|
(893 |
) |
|
|
(1,125 |
) |
|
|
(1,640 |
) |
Amortization of debt financing costs |
|
|
60 |
|
|
|
43 |
|
|
|
159 |
|
|
|
89 |
|
Non-cash lease expense |
|
|
75 |
|
|
|
11 |
|
|
|
256 |
|
|
|
60 |
|
Loss on disposal of property, plant and equipment |
|
|
210 |
|
|
|
— |
|
|
|
210 |
|
|
|
4 |
|
Goodwill impairment |
|
|
16,613 |
|
|
|
|
|
|
16,613 |
|
|
|
— |
|
Other |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
(10 |
) |
Changes in operating assets and liabilities: |
|
|
|
|
|
|
|
|
|
|
|
|
Accounts receivable |
|
|
227 |
|
|
|
(504 |
) |
|
|
(949 |
) |
|
|
(170 |
) |
Contract assets |
|
|
(667 |
) |
|
|
— |
|
|
|
(667 |
) |
|
|
— |
|
Inventories |
|
|
(2,600 |
) |
|
|
(500 |
) |
|
|
(5,107 |
) |
|
|
(1,497 |
) |
Income taxes receivable |
|
|
(3 |
) |
|
|
447 |
|
|
|
1,068 |
|
|
|
226 |
|
Prepaid expenses and other current assets |
|
|
(1,820 |
) |
|
|
(2,195 |
) |
|
|
(1,083 |
) |
|
|
(1,777 |
) |
Other non-current assets |
|
|
(407 |
) |
|
|
2 |
|
|
|
(996 |
) |
|
|
(5 |
) |
Accounts payable |
|
|
1,247 |
|
|
|
501 |
|
|
|
969 |
|
|
|
468 |
|
Accrued liabilities |
|
|
(283 |
) |
|
|
348 |
|
|
|
343 |
|
|
|
553 |
|
Other |
|
|
(21 |
) |
|
|
(17 |
) |
|
|
(61 |
) |
|
|
(70 |
) |
Cash used in operating activities |
|
|
(8,332 |
) |
|
|
(4,837 |
) |
|
|
(19,371 |
) |
|
|
(5,987 |
) |
Investing activities: |
|
|
|
|
|
|
|
|
|
|
|
|
Purchase of property, plant and equipment |
|
|
(6,582 |
) |
|
|
(3,907 |
) |
|
|
(23,419 |
) |
|
|
(12,465 |
) |
Proceeds from loan to related party |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
529 |
|
Proceeds on sales of short-term marketable securities |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
1,132 |
|
Proceeds from maturities of short-term marketable securities |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
695 |
|
Cash used in investing activities |
|
|
(6,582 |
) |
|
|
(3,907 |
) |
|
|
(23,419 |
) |
|
|
(10,109 |
) |
Financing activities: |
|
|
|
|
|
|
|
|
|
|
|
|
Proceeds from long-term debt |
|
|
— |
|
|
|
1 |
|
|
|
5,135 |
|
|
|
11,890 |
|
Payment of debt issuance costs |
|
|
— |
|
|
|
— |
|
|
|
(151 |
) |
|
|
(153 |
) |
Payment of exit fee costs |
|
|
— |
|
|
|
— |
|
|
|
(135 |
) |
|
|
— |
|
Payment of costs related to initial public offering |
|
|
— |
|
|
|
(1,266 |
) |
|
|
— |
|
|
|
(3,615 |
) |
Proceeds from initial public offering, net of underwriters’
commissions and discounts |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
102,672 |
|
Proceeds from exercise of stock options |
|
|
35 |
|
|
|
— |
|
|
|
134 |
|
|
|
— |
|
Proceeds from issuance of common stock under employee stock
purchase plan |
|
|
— |
|
|
|
— |
|
|
|
144 |
|
|
|
— |
|
Cash provided by financing activities |
|
|
35 |
|
|
|
(1,265 |
) |
|
|
5,127 |
|
|
|
110,794 |
|
Change in cash and cash equivalents |
|
|
(14,879 |
) |
|
|
(10,009 |
) |
|
|
(37,663 |
) |
|
|
94,698 |
|
Cash and cash equivalents at beginning of period |
|
|
64,734 |
|
|
|
108,022 |
|
|
|
87,518 |
|
|
|
3,315 |
|
Cash and cash equivalents at end of period |
|
$ |
49,855 |
|
|
$ |
98,013 |
|
|
$ |
49,855 |
|
|
$ |
98,013 |
|
ALPHA TEKNOVA, INC.
Reconciliation of Non-GAAP Measures to the Most Comparable
GAAP Measures (Unaudited) (In
thousands)
|
|
For the Three Months EndedSeptember 30, |
|
|
For the Nine Months EndedSeptember 30, |
|
|
|
2022 |
|
|
2021 |
|
|
2022 |
|
|
2021 |
|
Net loss – as reported |
|
$ |
(22,474 |
) |
|
$ |
(3,251 |
) |
|
$ |
(34,174 |
) |
|
$ |
(6,156 |
) |
Add back: |
|
|
|
|
|
|
|
|
|
|
|
|
Interest income (expense), net |
|
|
70 |
|
|
|
(255 |
) |
|
|
85 |
|
|
|
(553 |
) |
Benefit from income taxes |
|
|
(374 |
) |
|
|
(892 |
) |
|
|
(1,128 |
) |
|
|
(1,640 |
) |
Depreciation expense |
|
|
442 |
|
|
|
461 |
|
|
|
1,411 |
|
|
|
1,239 |
|
Amortization of intangible assets |
|
|
287 |
|
|
|
287 |
|
|
|
861 |
|
|
|
861 |
|
EBITDA |
|
$ |
(22,189 |
) |
|
$ |
(3,140 |
) |
|
$ |
(33,115 |
) |
|
$ |
(5,143 |
) |
Other and one-time expenses: |
|
|
|
|
|
|
|
|
|
|
|
|
Stock-based compensation expense |
|
|
968 |
|
|
|
442 |
|
|
|
2,689 |
|
|
|
927 |
|
Goodwill impairment charge |
|
|
16,613 |
|
|
|
— |
|
|
|
16,613 |
|
|
|
— |
|
Adjusted EBITDA |
|
$ |
(4,608 |
) |
|
$ |
(2,698 |
) |
|
$ |
(13,813 |
) |
|
$ |
(4,216 |
) |
|
|
For the Three Months EndedSeptember 30, |
|
|
For the Nine Months EndedSeptember 30, |
|
|
|
2022 |
|
|
2021 |
|
|
2022 |
|
|
2021 |
|
Cash used in operating activities |
|
$ |
(8,332 |
) |
|
$ |
(4,837 |
) |
|
$ |
(19,371 |
) |
|
$ |
(5,987 |
) |
Purchase of property, plant and equipment |
|
|
(6,582 |
) |
|
|
(3,907 |
) |
|
|
(23,419 |
) |
|
|
(12,465 |
) |
Free Cash Flow |
|
$ |
(14,914 |
) |
|
$ |
(8,744 |
) |
|
$ |
(42,790 |
) |
|
$ |
(18,452 |
) |
Investor Contacts
Matt Lowell
Chief Financial Officer
matt.lowell@teknova.com
+1 831-637-1100
Sara Michelmore
MacDougall Advisors
smichelmore@macdougall.bio
+1 781-235-3060
Media Contact
Jenn Henry
Senior Vice President, Marketing
jenn.henry@teknova.com
+1 831-313-1259
Alpha Teknova (NASDAQ:TKNO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Alpha Teknova (NASDAQ:TKNO)
Historical Stock Chart
From Apr 2023 to Apr 2024